ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Idorsia submits investigational insomnia treatment daridorexant to the EMA pharmatimes
March 03, 2021Swiss biotech company Idorsia has submitted a marketing authorisation application to the European Medicines Agency (EMA) for its investigational insomnia treatment daridorexant. -
Idorsia Partners with Syneos Health contractpharma
September 01, 2020?Idorsia Ltd and Syneos Health have formed a commercial relationship for the U.S. commercialization of Idorsia’s daridorexant, a new dual orexin receptor antagonist being investigated for the treatment of insomnia.
Pharma Sources Insight January 2025
